Philips received FDA 510(k) clearance for its Verida spectral CT system, the company’s first AI‑powered detector‑based spectral CT platform. The clearance was granted on March 27 2026, and Philips announced the approval on April 16 2026, allowing the company to market Verida in the United States.
Verida delivers always‑on spectral imaging combined with AI reconstruction, enabling faster exams and higher image quality. The system supports head, whole‑body, cardiac, and vascular CT, as well as low‑dose lung‑cancer screening. Its AI reconstruction, Spectral Precise Image, produces 145 images per second, supporting up to 270 exams per day.
The clearance aligns with Philips’ strategy to embed AI across its diagnostic imaging portfolio. By adding AI to its advanced CT platform, Philips can capture a larger share of the U.S. medical‑imaging market, where detector‑based spectral CT is increasingly sought for material differentiation and workflow efficiency.
Philips has installed over 800 spectral CT systems worldwide. Verida builds on that legacy while adding AI, giving Philips a competitive edge over rivals such as GE, Siemens, and Canon, who offer source‑based spectral CT or non‑AI solutions. The AI integration differentiates Verida in terms of speed, image quality, and clinical decision support.
Dan Xu, Business Leader of CT at Philips, said: “With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets. By combining always‑on spectral imaging with AI‑powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.” This statement underscores Philips’ confidence in the product’s clinical impact and its role in the broader AI strategy.
The approval also signals Philips’ continued investment in AI and cloud‑based imaging solutions. The company has been expanding its AI‑enabled platforms across MRI and digital pathology, and the Verida clearance is a key milestone in that trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.